BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21486935)

  • 1. A designed cell-permeable aptamer-based corepressor peptide is highly specific for the androgen receptor and inhibits prostate cancer cell growth in a vector-free mode.
    Reeb CA; Gerlach C; Heinssmann M; Prade I; Ceraline J; Roediger J; Roell D; Baniahmad A
    Endocrinology; 2011 Jun; 152(6):2174-83. PubMed ID: 21486935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
    J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells.
    Esmaeili M; Jennek S; Ludwig S; Klitzsch A; Kraft F; Melle C; Baniahmad A
    J Mol Cell Biol; 2016 Jun; 8(3):207-20. PubMed ID: 26993046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor.
    Yoon HG; Wong J
    Mol Endocrinol; 2006 May; 20(5):1048-60. PubMed ID: 16373395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
    Trtková K; Pašková L; Matiješčuková N; Kolář Z
    Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CCAAT enhancer-binding protein-alpha negatively regulates the transactivation of androgen receptor in prostate cancer cells.
    Chattopadhyay S; Gong EY; Hwang M; Park E; Lee HJ; Hong CY; Choi HS; Cheong JH; Kwon HB; Lee K
    Mol Endocrinol; 2006 May; 20(5):984-95. PubMed ID: 16455820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of ligand-specific co-repressor binding to the androgen receptor.
    Gerlach C; Roell D; Baniahmad A
    Methods Mol Biol; 2011; 776():199-223. PubMed ID: 21796529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sterol regulatory element-binding protein-1c represses the transactivation of androgen receptor and androgen-dependent growth of prostatic cells.
    Suh JH; Gong EY; Kim JB; Lee IK; Choi HS; Lee K
    Mol Cancer Res; 2008 Feb; 6(2):314-24. PubMed ID: 18245227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells.
    Buchanan G; Need EF; Barrett JM; Bianco-Miotto T; Thompson VC; Butler LM; Marshall VR; Tilley WD; Coetzee GA
    Mol Cell Endocrinol; 2011 Aug; 342(1-2):20-31. PubMed ID: 21664238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
    Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
    Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocyte nuclear factor-3 alpha (HNF-3alpha) negatively regulates androgen receptor transactivation in prostate cancer cells.
    Lee HJ; Hwang M; Chattopadhyay S; Choi HS; Lee K
    Biochem Biophys Res Commun; 2008 Mar; 367(2):481-6. PubMed ID: 18178153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity of cyclin D1 for androgen receptor regulation.
    Petre-Draviam CE; Cook SL; Burd CJ; Marshall TW; Wetherill YB; Knudsen KE
    Cancer Res; 2003 Aug; 63(16):4903-13. PubMed ID: 12941814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
    Jackson KM; Frazier MC; Harris WB
    Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative modulation of androgen receptor transcriptional activity by Daxx.
    Lin DY; Fang HI; Ma AH; Huang YS; Pu YS; Jenster G; Kung HJ; Shih HM
    Mol Cell Biol; 2004 Dec; 24(24):10529-41. PubMed ID: 15572661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.
    Hsieh CL; Cai C; Giwa A; Bivins A; Chen SY; Sabry D; Govardhan K; Shemshedini L
    J Mol Endocrinol; 2008 Jul; 41(1):13-23. PubMed ID: 18469090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation.
    Chen SY; Cai C; Fisher CJ; Zheng Z; Omwancha J; Hsieh CL; Shemshedini L
    Oncogene; 2006 Nov; 25(54):7212-23. PubMed ID: 16732317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
    Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential modulation of androgen receptor transcriptional activity by the nuclear receptor co-repressor (N-CoR).
    Berrevoets CA; Umar A; Trapman J; Brinkmann AO
    Biochem J; 2004 May; 379(Pt 3):731-8. PubMed ID: 14744261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
    Xie Y; Wolff DW; Lin MF; Tu Y
    Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S; Agoulnik IU; Weigel NL
    Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.